1,101 posts by 291 firms and lawyers
Cannabis law explained by the lawyers who practise it: analysis and commentary from law firms around the world, with the Cannabis Law Journal.
The Mexican Supreme Court of Justice (Suprema Corte de Justicia de la Nación, “SCJN”) recently issued a relevant decision further defining the scope of authorizations for the recreational self-consumption of cannabis and…
Congress just gave the hemp industry a little more time. Today, the House approved the Senate-passed Continuing Appropriations and Extensions Act, 2027, H.R. 6500, with its temporary hemp extension intact. The bill now goes to…
Source: https://www.linkedin.com/pulse/virginias-cannabis-program-picking-up-speed-rwmje/
Thailand’s cannabis regulatory framework continues to move away from the broad commercial liberalization that followed decriminalization in 2022. The latest regulatory developments do not amount to a full recriminalization of…
One of the most frequently cited reasons for slow cannabis reform in many jurisdictions is the obligation to comply with international drug control treaties, particularly the United Nations Single Convention on Narcotic Drugs.
With SF 4401, the state did not leave the hemp industry stranded while the broader cannabis market moves on. It did not wall off hemp operators and tell them to fend for themselves.
On April 28, 2026, Acting Attorney General Blanche (“AG”) issued a notice of hearing concerning the proposed rule to move marijuana from Schedule I to Schedule III of the Controlled Substances Act (“CSA”).
Massachusetts’ legal cannabis market is undergoing a transformation, with new rules that increase the amount of marijuana someone over 21 can purchase, ensure potency levels and restructure the Cannabis Control Commission, among…
On April 23, 2026, the United States Department of Justice and Drug Enforcement Administration announced an order reclassifying certain marijuana products from Schedule I to Schedule III under the Federal Controlled Substances…
Marijuana’s proposed move from Schedule I to Schedule III under the Controlled Substances Act has renewed focus on what rescheduling could mean for marijuana-related businesses (MRBs) and the financial institutions that serve…
Today, April 23, 2026, the United States Acting Attorney General, Todd Blanche, (the “AG”) and the U.S. Department of Justice (“DOJ”) announced the issuance of a final order that “immediately places” some cannabis into Schedule…
The rescheduling of certain cannabis products to Schedule III represents a meaningful shift in federal cannabis policy and offers long-awaited tax relief for portions of the industry.
On April 23, 2026, as we discussed in our prior client alert, the Department of Justice issued a Final Order immediately placing cannabis “subject to a state medical marijuana license” in Schedule III of the Controlled Substances…
Medical cannabis products moved to Schedule III and to become fully legal with DEA Registration; Possibility for Adult-Use Rescheduling in Upcoming Hearing
The U.S. has joined much of the world in acknowledging medical marijuana. Let international trading begin!
Most commentary on the “hemp ban” included in the November funding bill has focused on two related questions: (1) which products and activities may become unlawful on November 12, 2026; and (2) whether Congress will materially…
by mariana.cuzziol, Viviane Kunisawa | Feb 4, 2026 | Cannabis, Client Alert
On December 18, 2025, President Trump signed an executive order. It directed the Department of Justice to expedite rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act (CSA).
Authored and Edited by Hannah Whitmore, Ph.D.; K. Victoria Barker, Ph.D.; Victoria A. Randall, Ph.D.
As the number of private prescriptions for medical cannabis continues to rise, employers are faced with new considerations in the workplace. This article explores the issues.